mi-Opioid/D2 dopamine receptor pharmacophore containing ligands: Synthesis and pharmacological evaluation

Ivana I. Jevtić, Jelena Z. Penjišević, Katarina R. Savić-Vujović, Dragana P. Srebro, Sonja M. Vučković, Milovan D. Ivanović, Slađana V. Kostić-Rajačić

Abstract


Herein, the synthesis and pharmacological evaluation of 13 novel compounds, designed as potential heterobivalent ligands for m-opioid receptor (MOR) and dopamine D2 receptors (D2DAR), are reported. The compounds consisted of anilido piperidine and N-aryl piperazine moieties, joined by a variable-length methylene linker. The two moieties represent MOR and D2DAR pharmacophores, respectively. The synthesis encompassed four steps, securing the final products in 28–42 % overall yields. The approach has a con­siderable synthetic potential, providing access to various related structures. Pharmacological tests involved in vitro competitive assay for D2DAR using [3H] spiperon, as a standard radioligand, and in vivo antinociceptive tests for MOR. The measured dopamine affinities were modest to low, while antino­cic­eptive activity was completely absent. Therefore, the compounds of the general structure prepared in this research are unlikely to be useful as opioid–dopamine receptor heterobivalent ligands.

Keywords


piperidine; piperazine; heterobivalent; opioids; analgesics; dopaminergic

References


L. L. Brunton, R. Hilal-Dandan, B. C. Knollmann, Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13th ed., McGraw-Hill Education, New York, 2018, pp. 355–386 (https://books.google.rs/books?id=yAg7DwAAQBAJ&source=gbs_bo-ok_other_versions)

J. H. Harvey, D. H. Long, P. M. England, J. L. Whistler, Med. Chem. Lett. 3 (2012) 640 (https://doi.org/10.1021/ml300083p)

A. Manglik, A. C. Kruse, T. S. Kobilka, F. S. Thian, J. M. Mathiesen, R. K. Sunahara, L. Pardo, W. I. Weis, B. K. Kobilka, S. Granier, Nature 485 (2012) 321 (https://doi.org/10.1038/nature10954)

J. M. Bidlack, B. I. Knapp, in Research and Development of Opioid-Related Ligands, M.-C. Ko, S. M. Husbands, Eds., American Chemical Society, Washington, DC, 2013, pp. 257–272 (https://pubs.acs.org/doi/book/10.1021/bk-2013-1131)

A. Mollica, S. Pelliccia, V. Famiglini, A. Stefanucci, G. Macedonio, A. Chiavaroli, G. Orlando, L. Brunetti, C. Ferrante, S. Pieretti, E. Novellino, S. Benyhe, F. Zador, A. Erdei, E. Szucs, R. Samavati, S. Dvoracsko, C. Tomboly, R. Ragno, A. Patsilinakos, R. Sil¬vestri, J. Enzyme Inhib. Med. Chem. 32 (2017) 444 (https://doi.org/10.1080/14756366.2016.1260565)

C. D. Peterson, K. F. Kitto, E. Akgün, M. M. Lunzer, M. S. Riedl, L. Vulchanova, G. L. Wilcox, P. S. Portoghese, C. A. Fairbanks, Pain 158 (2017) 2431 (https://doi.org/10.1097/j.pain.0000000000001050)

R. Dutta, M. M. Lunzer, J. L. Auger, E. Akgün, P. S. Portoghese, B. A. Binstadt, Arthritis Res. Ther. 20 (2018) 154 (https://doi.org/10.1186/s13075-018-1661-5)

R. Vardanyan, G.Vijay, G. S. Nichol, L. Liu, I. Kumarasinghe, P. Davis, T. Vanderah, F. Porreca, J. Lai, V. J. Hruby, Bioorg. Med. Chem. 17 (2009) 5044 (https://doi.org/10.1016/j.bmc.2009.05.065)

A. Mollica, R. Costante, E. Novellino, A. Stefanucci, S. Pieretti, F. Zador, R. Samavati, A. Borsodi, S. Benyhe, I. Vetter, R. J. Lewis, Chem. Biol. Drug. Des. 86 (2015) 156 (https://doi.org/10.1111/cbdd.12479)

Y. Chen, Y. Fu, Y. An, J. Cao, J. Wang, J. Zhang, Clin. Exp. Pharmacol. Physiol. (2018) 1 (https://doi.org/10.1111/1440-1681.12889)

D. J. Heal, M. Hallam, M. Prow, J. Gosden, S. Cheetham, Y. K. Choi, F. Tarazi, P. Hutson, J. Psychopharmacol. 31 (2017) 770 (https://doi.org/10.1177/0269881117699607)

B. Gago, D. Suárez-Boomgaard, K. Fuxe, S. Brené, M. D. Reina-Sánchez, L. M. Rodríguez-Pérez, L. F. Agnati, A. de la Calle, A. Rivera, Brain Res. 1407 (2011) 47 (https://doi.org/10.1016/j.brainres.2011.06.046)

M. Qian, L. Vasudevan, J. Huysentruyt, M. D. P. Risseeuw, C. Stove, P. M. L. Vanderheyden, K. Van Craenenbroeck, S. Van Calenbergh, ChemMedChem 13 (2018) 944 (https://doi.org/10.1002/cmdc.201700787)

I. I. Jevtić, J. Z. Penjišević, M. D. Ivanović, S. V. Kostić-Rajačić, J. Serb. Chem. Soc. 84 (2018) 639 (https://doi.org/10.2298/JSC181002105J)

R. S. Vardanyan, J. P. Cain, S. M. Haghighi, V. K. Kumirov, M. I. McIntosh, A. J. Sandweiss, F. Porreca, V. J. Hruby, J. Heterocycl. Chem. 54 (2017) 1228 (https://doi.org/10.1002/jhet.2696)

V. Šukalović, M. Zlatović, D. Andrić, G. Roglić, S. Kostić-Rajačić, V. Šoškić, Arch. Pharm. Pharm. Med. Chem. 337 (2004) 502 (https://doi.org/10.1002/ardp.200400901)

M. Tomic, M. Kundakovic, B. Butorovic, B. Janac, D. Andric, G. Roglic, Dj. Ignjatovic, V. Soskic, S. Kostic-Rajacic, Bioorg. Med. Chem. Lett. 14 (2004) 4263 (https://doi.org/10.1002/ardp.201600081)

GraphPad Software Inc., GrapPad Prism, version 4.0, 2003 (https://www.graphpad.com/scientific-software/prism/)

S. Vučković, M. Prostran, M. Ivanović, Z. Ristović, R. Stojanović, Jpn. J. Pharmacol. 84 (2000) 188 (https://doi.org/10.1254/jjp.84.188)

R. J. Tallarida, R. B Murray, The Manual of pharmacologic calculations with computer programs, 2nd ed., Springer-Verlag, New York, 1986 (https://doi.org/10.1007/978-1-4612-4974-0)

S. Wang, T. Che, A. Levit, B. K. Shoichet, D. Wacker, B. L. Roth, Nature 555 (2018) 269 (https://doi.org/10.1038/nature25758)

W. Huang, A. Manglik, A. J. Venkatakrishnan, T. Laeremans, E. N. Feinberg, A. L. Sanborn, H. E. Kato, K. E. Livingston, T. S. Thorsen, R. Kling, S. Granier, P. Gmeiner, S. M. Husbands, J. R. Traynor, W. I. Weis, J. Steyaert, R. O. Dror, B. K. Kobilka, Nature 524 (2015) 315 (https://doi.org/10.1038/nature14886)

A. Koeh, H. Hu, S. Maeda, Y. Zhang, Q. Qu, J. M. Paggi, N. R. Latorracal, D. Hilger, R. Dawson, H. Matile, G. F. X. Schertler, S. Granier, W. I. Weis, R. O. Dror, A. Manglik, G. Skiniotis, B. K. Kobilka, Nature 558 (2018) 547 (https://doi.org/10.1038/s41586-018-0219-7)

L. N. Goswami, Z. H. Houston, S. J. Sarma, S. S. Jalisatgi, M. F. Hawthorne, Org. Biomol. Chem. 11 (2013) 1116 (https://doi.org/10.1039/C2OB26968F).




DOI: https://doi.org/10.2298/JSC190912118J

Copyright (c) 2019 Journal of the Serbian Chemical Society

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

IMPACT FACTOR 1.097
5 Year Impact Factor 1.023
(
138 of 177 journals)